A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.
Of the few preclinical IPOs, Metagenomi keeps details about IND plans close
There’s no word yet on when Metagenomi will enter the clinic. In its first quarterly update as a public company, the California biotech said Wednesday
March 29, 2024